• Explore /
  • Poster
  • / A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).

A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).

Abstract Poster

Authors

null

T.R. Jeffry Evans

University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom;

T.R. Jeffry Evans , Bristi Basu , Richard Hubner , Yuk Ting Ma , Tim Meyer , Daniel H. Palmer , David J. James Pinato , Elizabeth Ruth Plummer , Paul J. Ross , Adel Samson , Debashis Sarker , Timothy Kendall , Christopher Bellamy , Helen L Reeves , Fiona Thomson , Claire A Lawless , Jamie Stobo , Owen J Sansom , Derek A. Mann , Thomas G Bird

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

2020-003346-36

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS631)

DOI

10.1200/JCO.2023.41.4_suppl.TPS631

Abstract #

TPS631

Poster Bd #

N20

Abstract Disclosures

Similar Posters

First Author: Diane Damotte

First Author: David Silva Moura

First Author: Alberto Carretero-Gonzalez

First Author: Bahar Saberzadeh Ardestani